๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck

โœ Scribed by Jennifer E. Tseng; Bonnie S. Glisson; Fadlo R. Khuri; Dong M. Shin; Jeffrey N. Myers; Adel K. El-Naggar; Jennifer S. Roach; Lawrence E. Ginsberg; Peter F. Thall; Xuemei Wang; Stephanie Teddy; Kristie N. Lawhorn; Rebecca E. Zentgraf; Ganene D. Steinhaus; James M. Pluda; James L. Abbruzzese; Waun Ki Hong; Roy S. Herbst

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
241 KB
Volume
92
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Vinblastine, bleomycin and cisplatin for
Vinblastine, bleomycin and cisplatin for recurrent or metastatic squamous cell carcinoma of the head and neck
โœ David J. Perry; Martin D. Weltz; Archie W. Brown Jr; Robert L. Henderson; Willia ๐Ÿ“‚ Article ๐Ÿ“… 1982 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 315 KB ๐Ÿ‘ 2 views

Forty-two patients with recurrent or metastatic squamous cell carcinoma of the head and neck were treated with vinblastine, bleomycin, and cisplatin. All patients had received prior surgery, radiation or chemotherapy and all had measurable disease. Forty-five percent of the patients responded with a

A phase II study of adriamycin in previo
A phase II study of adriamycin in previously untreated squamous cell carcinoma of the head and neck
โœ Melody A. Cobleigh; James H. Hill; Patricia A. Gallagher; Lawrence J. Kukla; Tho ๐Ÿ“‚ Article ๐Ÿ“… 1985 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 278 KB ๐Ÿ‘ 1 views

Twenty patients with squamous cell carcinoma of the head and neck (SCC H/N) were treated with Adriamycin (doxorubicin) at a dosage of 60 mg/m\* at 3-week intervals. No patient had received surgery, radiation, or chemotherapy before treatment with Adriamycin. Responses were observed in 44% of 18 eval

A phase II study of cisplatin and contin
A phase II study of cisplatin and continuous infusion of vindesine in metastatic head and neck squamous cell cancer
โœ Eduardo Tellez-Bernal; Gonzalo Recondo; Thierry Guillot; Mohamed Benhamed; Chris ๐Ÿ“‚ Article ๐Ÿ“… 1990 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 456 KB ๐Ÿ‘ 1 views

The chemotherapeutic treatment of recurrent and/or metastatic squamous cell carcinoma (SCC) of the head and neck (H & N) has a very dismal prognosis, with survival usually not exceeding 1 year. Reported objective response rates vary between 3% and 70%. This difference appears largely attributable to